Glutathione peroxidases
Rather than randomizing individuals with T2D and established CVD to placebo, participants received either tirzepatide or dulaglutide, with the assumption that dulaglutide preserved a cardiovascular benefit of at least 12% over placebo as observed in REWIND
The data announced in December 2025 was impressive: Weight loss: Participants on the 12mg dose lost an average of 28.7% of their body weight (32.3 kg or 71.2 pounds) over 68 weeks
Gene Expression 2018 4,048 Gene Expression Changes Identified Comprehensive analysis of GHK-Cus regenerative and protective actions in light of new gene expression data, demonstrating modulation of pathways for tissue remodeling, antioxidant response, and anti-inflammatory signaling
Theranostic self-assembly structure of gold nanoparticles for NIR photothermal therapy and X-ray computed tomography imaging
Timeline for Canadian Availability While Apotex has achieved tentative FDA approval, the company's Health Canada application remains under review
